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Abstract
Background: To evaluate quality of life, functional and oncological outcome after infravesical desobstruction and
HIFU treatment for localized prostate cancer.
Methods: One hundred thirty-one patients, treated with TURP and HIFU in a single institution were followed up for
oncological and functional outcome. Oncological outcome was quantified by biochemical recurrence free survival
using the Stuttgart and Phoenix criteria. Quality of life was assessed by usage of standardized QLQ-C30 and QLQ-
PR25 questionnaires. In addition, functional questionnaires such as IPSS and IIEF-5 were used. Complications were
assessed by the Clavien-Dindo classification.
Results: One hundred thirty-one patients with a mean age of 72.8 years (SD: 6.0) underwent HIFU for prostate cancer
(29.0% low risk, 58.8% intermediate risk, 12.2% high risk). PSA nadir was 0.6 ng/ml (SD: 1.2) after a mean of 4.6 months
(SD: 5.7). Biochemical recurrence free survival defined by Stuttgart criteria was 73.7%, 84.4% and 62.5% for low-,
intermediate- and high-risk patients after 22.2 months. Complications were grouped according to Clavien-Dindo and
occurred in 10.7% (grade II) and 11.5% (grade IIIa) of cases. 35.1% of patients needed further treatment for bladder neck
stricture. Regarding incontinence, 14.3%, 2.9% and 0% of patients had de novo urinary incontinence grade I°, II° and III°
and 3.8% urge incontinence due to HIFU treatment. Patients were asked for the ability to have intercourse: 15.8%, 58.
6% and 66.7% of patients after non-, onesided and bothsided nervesparing procedure were able to obtain sufficient
erection for intercourse, respectively. Regarding quality of life, mean global health score according to QLQ-C30 was 69.
4%.
Conclusion: HIFU treatment for localized prostate cancer shows acceptable oncological safety. Quality of life after HIFU
is better than in the general population and ranges within those of standard treatment options compared to literature.
HIFU seems a safe valuable treatment alternative for patients not suitable for standard treatment.
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Background
High intensified focused ultrasound (HIFU) is a minimal
invasive, thermoablative treatment option for patients
with localized prostate cancer. Its aim is equivalent
oncological safety with reduced toxicity, compared to
standard treatment options [1]. HIFU can be performed
in general or spinal anesthesia via transrectal approach.
Focused, high energetic ultrasound waves cause thermal
alteration and cavitation, causing coagulative necrosis
and thereby destroying malignant tissue [2, 3].
Since the initial presentation in 1995 [4], several stud-
ies have evaluated oncological and functional outcome
after HIFU. Recent publications report of 76%, 63% and
57% biochemical free survival after 8 years for low-,
intermediate- and high-risk patients [5]. The 10-year
prostate cancer specific survival rate and metastasis-free
survival rate were 97% and 94%, respectively [5]. Regard-
ing morbidity of HIFU treatment, severe incontinence
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rates of 3.1% and erectile function preservation of up to
42.3% are described [5]. Patients rejecting standard treat-
ment and preferring HIFU do this with the expectation
for less complications and less invasiveness compared to
standard treatment. Especially incontinence, erectile
dysfunction after radical prostatectomy as well as gastro-
intestinal and genitourinary side effects after radiother-
apy are feared by many patients and can impair their
quality of life [6]. Recent studies have evaluated quality
of life for prostate cancer patients after local therapy,
showing good results with moderate alteration in erectile
and lower urinary tract function with minimal decrease
in quality of life [7, 8]. The authors utilized standardized
questionnaires for this evaluation like the European Or-
ganisation for Research and Treatment of cancer
(EORTC) quality of life questionnaire QLQ-C30 and the
prostate specific module QLQ-PR25. The QLQ-C30
questionnaire evaluates overall health related quality of
life as well as several functional domains and general
cancer related symptoms. The QLQ-PR25 assesses urin-
ary symptoms, sexual activity and function, as well as
bowel symptoms. Both questionnaires have been evalu-
ated and validated extensively [9, 10]. Regarding quality
of life for prostate cancer patients, both questionnaires
are routinely used.
To our knowledge, data about quality of life after
HIFU therapy using standardized questionnaires are rare
and have not been evaluated in a standardized fashion
so far. The aim of the study was to investigate prospect-
ively quality of life after HIFU ablation of the prostate
for the local treatment of prostate cancer.
Methods
One hundred thirty-one patients undergoing infravesical
desobstruction and HIFU treatment for localized pros-
tate cancer between 02/2008 and 12/2012 were followed
up in a prospectively conducted database. The study
protocol was approved by the ethics committee of the
University of Heidelberg (S-182/2012). All patients gave
written informed consent.
All patients were treated with the Ablatherm HIFU de-
vice (Ablatherm integrated imaging device; EDAP-TMS,
Vaulx-en-Velin, France). Before HIFU treatment an
infravesical desobstruction was routinely done one day
prior to HIFU treatment, normally by transurethral re-
section of the prostate (TURP) or by greenlight laserva-
porisation of the prostate [11]. The mode of infravesical
desobstruction was at patients’ preference (TUR-P was
recommended, some patients explicitly wished to
undergo greenlight laservaporisation). HIFU treatment
was performed as inpatient procedure in combined
spinal and epidural anesthesia. Nervesparing procedure
was only done in patients explicitly demanding for this.
All these patients were intensively informed about
higher risk for recurrent prostate cancer but wished to
undergo nervesparing anyway and with awareness of all
risks (this was also documented in informed consent). In
these cases, mainly one sided nervesparing was done - if
prostate biopsy showed cancer infiltration on only one
side the nervesparing was done on the contralateral side.
However, some patients explicitly wished both sided
nervesparing, taking into account the risk for tumor
recurrence. For all patients, the following parameters
were assessed and entered in a prospective conducted
database: patient age, body mass index, prostate volume,
PSA value at diagnosis, Gleason Score, clinical stage,
risk classification (according to D’Amico et al. [12, 13]),
PSA nadir and time to PSA nadir, biochemical recur-
rence according to Stuttgart criteria [14] and Phoenix
criteria [15]. In addition, treatment related data were eval-
uated and included: type of preoperative infravesical deso-
bstruction, duration and number of applied lesions during
HIFU treatment, nervesparing (non-,unilateral-,bilateral
nervesparing), hospital stay, indwelling time for trans-
urethral and suprapubic catheter, uroflowmetry and
residual volume (pre-HIFU and 2 weeks post-HIFU). In
addition, complication were evaluated according to
Clavien-Dindo [16]. Patients were asked to fill out the
international prostate symptom score (IPSS) and inter-
national index for erectile function (IIEF-5) question-
naire before and 3 months after HIFU treatment.
Continence was evaluated and graduated during follow-
up, the usage and number of used pads was evaluated.
Patients were also asked for sexual activity after HIFU
treatment including the usage of adjuvant medication
for erection.
Assessment of quality of life
All patients were asked to complete the European Or-
ganisation for Research and Treatment of cancer
(EORTC) quality of life questionnaire QLQ-C30 (Ver-
sion 3.0) and the prostate specific module QLQ-PR25
retrospectively in 12/2012. Both questionnaires are inter-
nationally validated and used in cancer patients. They
were used in German translation. The QLQ-C30 ques-
tionnaire consists of 30 questions, the QLQ-PR25 of 25
questions. The QLQ-C30 measures global health related
quality of life, five functional domains (physical, role,
emotional, cognitive and role function) and nine symp-
tom scales (fatigue, nausea and vomiting, pain, dyspnoe,
insomnia, appetite loss, constipation, diarrhea, financial
difficulties). The QLQ-PR25 questionnaire, consisting of
25 questions, assesses urinary symptoms, bowel symp-
toms, treatment-related symptoms and sexual symptoms
and functioning. In both instruments, all answers ranged
from 1 (not at all) to 4 (very much), despite 2 questions
in the QLQ-C30 considering global health related qual-
ity of life ranging from 1 (very poor) to 7 (excellent).
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Both questionnaires have been interpreted according to
the EORTC guidelines. The scores have been converted
to linear scales ranging from 0 to 100. Higher values in
functional scales and health related quality of life repre-
sent better results. Lower values in symptom scales rep-
resent less symptoms.
Statistical analysis
Above mentioned variables were evaluated by descriptive
statistics. Median, mean, standard deviation and range
were calculated for every variable using Microsoft Excel
and IBM SPSS statistics version 20.
Results
One hundred thirty-one patients with a mean age of
72.8 ± 6.0 years have been included to this analysis. PSA
values at prostate cancer diagnosis were 9.6 ± 14.9 ng/
ml. Gleason score was 6 in 57 patients (43.5%), 7 in 66
patients (50.4%) and ≥ 8 in 8 patients (6.1%). 29.0% of
patients had a low risk, 58.8% an intermediate risk and
12.2% a high risk prostate cancer (Table 1). When pre-
senting for HIFU treatment, 28 patients (21.4%) have
been on neoadjuvant hormonal therapy, that has been
stopped directly after HIFU treatment. Bothsided nerve-
sparing was performed in 21.1%, 9.6% and 6.7%,
onesided nervesparing in 28.9%, 26.0% and 6.7% of low-,
intermediate- and high-risk patients, respectively. After
HIFU the mean PSA nadir was 0.6 ± 1.2 ng/ml (median:
0.1 ng/ml; range 0.01-6.50 ng/ml) and reached after
4.7 months (SD: 5.7) (Table 2). Mean follow up was
22.2 months (SD: 16.1). 28 patients (21.4%) developed a
biochemical recurrence, defined as PSA Nadir + 1.2 ng/
ml (according to Stuttgart criteria [14]) after a mean
time of 15.5 ± 11.6 months. Among them, 10 patients
(26.3%), 12 patients (15.6%) and 6 patients (37.5%) of
low-, intermediate-and high-risk profile, respectively.
Therefore, biochemical recurrence free survival was
73.7%, 84.4% and 62.5% for low-, intermediate- and
high-risk patients at latest follow-up. In addition, 3 pa-
tients had histological confirmed recurrence that was
confirmed in prostate biopsy in patients undergoing bi-
opsy after 6 months at own wish or after bladder neck
resection due to infravesical obstruction.
Of these 31 patients with recurrent prostate cancer, 18
patients (58.1%) underwent active therapy. Twelve of
these patients were lost to follow-up. Five patients
underwent salvage radiotherapy, two 2 patients salvage-
HIFU therapy, one patient prostatectomy and one pa-
tient brachytherapy and pelvic lymphadenectomy. The
other 9 patients (29.0%) did not wish salvage therapy
and received antiandrogen treatment. During follow-up,
7 patients (5.3%) deceased – 1 patient because of sys-
temic progression of the prostate cancer, the other 6 pa-
tients due to cardiovascular events (Table 3).
When defining biochemical recurrence according to
Phoenix criteria, 20 patients (15.5%) showed biochemical
recurrence with a mean time to recurrence of 17.4 ±
12.5 months. Biochemical recurrence free survival was
therefore 81.6%, 89.6% and 68.8% for low-, intermediate-
and high-risk patients at latest follow-up, respectively.
Regarding treatment data, 109 patients (83.2%) under-
went TUR-P, 18 patients greenlight-laser vaporization
(13.7%) and 1 patient (0.8%) combination of both in ad-
vance to HIFU treatment. Resection was done the day
prior to HIFU. Mean prostate size was thereby reduced
from 43.7 ml (±25.6) to 26.0 ml (±12.5). Three patients
(2.3%) had no prior infravesical desobstruction. During
HIFU treatment, a one-sided nervesparing was done in
31 patients (23.7%), a both sided nervesparing in 16 pa-
tients (12.2%). Perioperative side effects up to 30 days
after HIFU treatment were assessed and grouped ac-
cording to Clavien-Dindo classification and occurred in
Table 1 Demographics
n (%) mean (SD)
Age (years) 131 72.8 (6.0)
Clinical stage
cT1 83 (63.8%)
≥ cT2 47 (36.2%)
Gleason Score
≤ 6 57 (43.5%)
7 66 (50.4%)
≥ 8 8 (6.1%)
inital PSA (ng/ml) 130 9.6 (14.9)
Risk stratification (D’Amico)
Low - risk 38 (29.0%)
Intermediate - risk 77 (58.8%)
High - risk 16 (12.2%)
Prostate volume (ml) 130 43.7 (25.6)
Prostate volume after resection 123 26.0 (12.5)
Table 2 Perioperative parameter
n (%) mean (SD)
Treated HIFU volume (ml) 126 27.7 (9.9)
Duration of HIFU treatment (minutes) 127 104.3 (28.8)
Applied lesions 127 433.8 (136.2)
Nervesparing
No nervesparing 79 (60.3%)
One-sided nervesparing 31 (23.7%)
Both-sided nervesparing 16 (12.2%)
Data missing 5 (3.8%)
Transurethral catheter indwelling time 125 4.0 (2.5)
Suprapubic catheter indwelling time 78 14.5 (15.0)
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25 patients (19.1%), 4 patients had 2 complications.
Main complications were infravesical obstruction and
urinary tract infections. With respect to infravesical ob-
struction, grade II and grade IIIa complications occurred
in 14 (10.7%) and 15 (11.5%) cases, respectively. Regard-
ing late complications beyond 30 days, 47 patients
(35.9%) needed further treatment. 46 patients (35.1%)
needed catheterization or suprapubic catheter insertion
and transurethral resection because of bladder neck ob-
struction. One patients needed DJ insertion because pro-
gression of prostate cancer.
IPSS score before and after HIFU treatment was 10.9
± 7.1 and 9.2 ± 6.2, respectively. Uroflowmetrie before
and after HIFU treatment showed max. flow of 14.0 ml/
s (SD 8.2) and 14.1 ml/s (SD 8.7) with post voiding re-
sidual volume of 45.5 ml (SD 69.4) and 54.0 ml (SD
93.6), respectively. Regarding incontinence, 14.3%, 2.9%
and 0% of patients had de novo urinary incontinence
grade I°, II° and III° and 3.8% urge incontinence due to
HIFU treatment. Before HIFU treatment 97.1% of pa-
tients did not need a pad. After HIFU treatment, 9.5%,
6.7% and 1.9% of patients needed 1pad, 2pads or >2pads,
respectively, meaning 81.9% did not need a pad at all at
latest follow-up.
IIEF-5 scores showed 17.2 ± 7.3 and 9.7 ± 8.0 before
and after HIFU treatment in all patients, respectively.
When grouped according to nervesparing procedure,
mean IIEF-5 score before and after HIFU was 15.1 ± 8.1
vs. 7.5 ± 7.4 for the non-nervesparing group, 19.7 ± 4.8
vs. 12.5 ± 8.3 for the one-sided nervesparing group and
20.7 ± 5.3 and 12.1 ± 7.5 for the both sided nervesparing
group, respectively. Regarding the ability to have sexual
intercourse, 15.8%, 58.6% and 66.7% of patients after non-,
onesided and bothsided nervesparing procedure were able
to obtain sufficient erection for intercourse, respectively.
33.3% of these patients used PDE5 inhibitors, 3 patients
mechanical devices to obtain erection. Functional out-
comes after HIFU therapy are displayed in Table 4.
Quality of life was evaluated using the QLQ-C30 ques-
tionnaire and showed a global health status of 69.4%
(SD: 20.6). Functional scales revealed physical function-
ing of 86.2% (SD 17.7) after HIFU treatment. Regarding
symptom scales, fatigue and insomnia were the most fre-
quent symptoms with 25.9% (SD: 24.8) and 31.4% (SD:
31.4) of cases in a cohort of men aged 72.8 ± 6.0 years.
For further evaluation of prostate specific symptoms the
QLQ-PR25 questionnaire was used and showed sexual
activity and functioning of 56.9% (SD: 28.1) and 49.6%
(SD: 20.5), respectively. Evaluation of symptom scales
showed urinary symptoms in 28.3% (SD: 18.4) and
Table 4 Functional outcome after HIFU treatment (mean(SD))
Pre - HIFU Post - HIFU
Continence and micturation symptoms
IPSS – Score 10.9 (7.1) 9.2 (6.2)
Micturation volume (ml) 207.7 (116.5) 189.2 (92.4)
Post voiding Residual volume(ml) 45.5 (69.4) 54.0 (93.6)
Qmax (ml/sec) 14.0 (8.2) 14.1 (8.7)
Continence
Continent 93 (88.6%) 71 (67.6%)
Incontince grade I° 5 (4.8%) 20 (19.0%)
Incontince grade II° 0 (0.0%) 3 (2.9%)
Incontince grade III° 1 (1.0%) 1 (1.0%)
Urge incontinence 6 (5.7%) 10 (9.5%)
Pad usage
No pads 102 (97.1%) 86 (81.9%)
1 pad 1 (1.0%) 10 (9.5%)
2 pads 1 (1.0%) 7 (6.7%)
> 2 pads 1 (1.0%) 2 (1.9%)
Sexual function
Sexual intercourse after HIFU
Yes 36 (35.6%)
No 65 (64.4%)
Due to HIFU treatment 46 (45.5%)
Other reason 55 (54.5%)
IIEF – 5
IIEF - 5 – score 17.2 (7.3) 9.7 (8.0)
IIEF - 5 - non – nervesparing 15.1 (8.1) 7.5 (7.4)
IIEF - 5 - onesided - nervesparing 19.7 (4.8) 12.5 (8.3)
IIEF - 5 - bothsided – nervesparing 20.7 (5.3) 12.1 (7.5)
Table 3 Oncological outcome
n (%) Mean (SD)
PSA – nadir (ng/ml) 101 0.6 (1.2)
median: 0.1
(range: 0.01–6.50)





low - risk - PCa 10 (7.6%)
intermediate - risk – PCa 12 (9.2%)
high - risk – PCa 6 (4.6%)
Time to BCR (in months)
(Stuttgart criteria)
28 15.5 (11.6)
Time to BCR (in months)
(Phoenix criteria)
17.4 (12.5)
low - risk - PCa 10 14.1 (8.2)
intermediate - risk - PCa 12 19.8 (13.8)
high - risk – Pca 6 11.3 (5.4)
Recurrence without BCR 3 (2.3%)
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urinary bother in 38.6% (SD: 35.6) of patients after
HIFU. Bowel symptoms did appear in 6.7% (SD: 11.2) of
patients. The overall quality of life did not change before
and after HIFU (evaluated by the IPSS questionnaire).
All results are displayed in Table 5.
Discussion
The present study was performed to evaluate quality of
life after HIFU treatment for prostate cancer. To our
knowledge, this is the first study investigating this topic.
Quality of life was assessed by standardized question-
naires. In addition, functional outcome and oncological
results were evaluated with respect to limited followup.
Regarding oncological results, recent reports from
Crouzet et al. showed 7 years biochemical free survival
(Phoenix Criteria) in 75%, 63% and 62% for low-, inter-
mediate- and high-risk prostate cancer patients [5].
Using the recently supposed stricter Stuttgart criteria
(meaning PSA nadir +1.2 ng/ml [14]), Pfeiffer et al. de-
scribed 5 years biochemical free survival as 85%, 65%
and 55% for low-, intermediate- and high-risk prostate
cancer [17]. The present series mainly consisted of inter-
mediate risk patients (58.8%) because high risk patients
were consulted for standard treatment and low risk pa-
tients for active surveillance. In this cohort, biochemical
recurrence free survival was 76.3%, 84.4% and 64.7%
(using Stuttgart criteria) and 81.6%, 89.6% and 68.8%
(using Phoenix criteria) for low-, intermediate- and
high-risk patients with a mean follow up of 22.2 months.
However, 3 patients of our cohort also had histological
proven recurrence without biochemical recurrence. Previ-
ous studies by Ganzer et al. showed, that negative biopsy
rates correlate with postoperative PSA nadir. Ganzer et al.
described negative biopsy rates of 91.6% for patients with
PSA nadir ≤ 0.2 ng/ml. Thus, 8.4% of patients had
remaining prostate cancer tissue in control biopsies after
3–6 months [14] with a PSA value < 0.2 ng/ml.
In our cohort, side effects were limited in severity. Main
complications were urinary tract infections and infravesi-
cal obstruction. While infections were mainly managed
successfully by antibiotic treatment, 25% of patients
needed further surgical treatment in form of transurethral
resection of bladder neck strictures. These complications
and rates were also described in other publications as the
most frequent re-interventions [18–20]. More severe
complications like fistulas did not occur in our cohort. Re-
garding postoperative micturition and continence, IPSS
and uroflowmetry data did not change after HIFU treat-
ment. Previous studies could show, that combining TURP
and HIFU is mandatory to reduce postoperative voiding
dysfunction [21]. However, even previous TURP cannot
reduce infravesical obstruction completely. During follow-
up, 35.1% of patients needed further treatment for infrave-
sical obstruction after HIFU treatment. Previous studies
confirm, that bladder neck obstruction or urethral stric-
tures are the most common side effects of HIFU treat-
ment [5, 18]. Crouzet et al. described up to 16% bladder
neck obstruction in their group, when TUR-P and HIFU
were combined in one session. To reduce these side ef-
fects, an interval of up to 6 weeks between TUR-P and
HIFU has been proposed [11] with reduction of infravesi-
cal obstruction to 11%, as described by Crouzet et al. [5].
Compared to our cohort, median pre-HIFU prostate vol-
ume was smaller in the cohort described by Crouzet et al.
(22–24.5 ml) compared to our cohort (38.5 ml), which
could explain the higher bladder neck obstruction rates in
the present study due to a selection bias.
Evaluation of erectile function in our group re-
vealed, that postoperative erectile function depends
Table 5 Quality of life – post-HIFU outcome of QLQ-C30, QLQ-
PR25 and IPSS-QoL questionnaires (n = 105). Data are shown as
mean with standard deviation
QLQ - C30
Global health status/QoL (QL2) 69.4 (20.6)
Functional scales
Physical functioning (PF2) 86.2 (17.7)
Role functioning (RF2) 79.0 (29.9)
Emotional functioning (EF) 74.8 (23.5)
Cognitive functioning (CF) 83.3 (20.5)
Social functioning (SF) 74.8 (25.0)
Symptom scales/items
Fatigue (FA) 25.9 (24.8)
Nausea and vomiting (NV) 1.5 (6.7)
Pain (PA) 17.1 (27.8)
Dyspnoea (DY) 18.1 (26.6)
Insomnia (SL) 31.4 (31.4)
Appetite loss (AP) 4.8 (16.9)
Constipation (CO) 16.2 (27.0)
Diarrhoea (DI) 7.3 (19.6)
Financial difficulties (FI) 10.5 (23.3)
QLQ - PR25
Functional scales
Sexual activity(PRSAC)(n = 104) 56.9 (28.1)
Sexual functioning (PRSFU)(n = 71) 49.6 (20.5)
Symptom scales/items
Urinary symptoms (PRURI) 28.3 (18.4)
Urinary bother (PRAID) 38.6 (35.6)
Bowel symptoms (PRBOW) 6.7 (11.2)
ADT – treatments symptoms (PRHTR) 16.4 (16.4)
Quality - of - life; IPSS
Prä - HIFU 2.1 (1.4)
Post - HIFU 2.0 (1.3)
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on nervesparing procedure. Most studies do not report of
nervesparing as this means sparing a few millimeters of
prostatic tissue and therefore increasing the risk for bio-
chemical recurrence [22]. As expected, the PSA nadir
ranges were higher (up to 6.5 ng/ml), most likely because
of nervesparing procedure, that has been done in 35.9% of
patients. Warmuth et al. [18] reviewed 20 studies with a
total of 3018 patients undergoing whole gland ablation and
reported of erectile dysfunction rates ranging from 20–
39%. Crouzet et al. [5] recently reported their results of
1002 patients and described preservation of erectile func-
tion in 42.3% patients (<70 years: 55.6%; >70 years: 25.6%).
None of these trials took nervesparing procedure into ac-
count. In our cohort, erectile function could be preserved
in only 15% in patients undergoing whole gland ablation.
These patients tended to be of advanced age (mean age in
non-nervesparing group was 74.4 years), that is known to
be associated with impaired baseline potency status [23]
and therefore these patients normally do not wish nerve-
sparing procedure. In contrast, both sided nervesparing
HIFU could preserve erectile function in up to 66% of our
patients (median age in this group was 69.7 years).
Patients undergoing HIFU ablation instead of standard
treatment commonly expect less side effects and better
preservation of quality of life. As quality of life repre-
sents a multidimensional construct that includes phys-
ical, social, psychological and functional domains, its
assessment needs complex and standardized question-
naires. Shoji et al. examined the changes in quality of life
for patients at a mean age 68 years undergoing HIFU by
using the japanese versions of the FACT-G and FACT-P
questionnaires (functional assessment of cancer therapy
– general and prostate cancer module) [24]. The authors
reported, that general quality of life improves after HIFU
therapy while the values for FACT-P questionnaire did
not change. However, patients undergoing HIFU may be
biased as they actively rejected standard therapy for a
new, minimal invasive therapy option. We evaluated
quality of life after HIFU therapy using the standardized
QLQ-C30 and QLQ-PR25 questionnaire. Mean global
health score after HIFU treatment was 69.4% for all pa-
tients, 66.4% for patients ≤70 years and 70.9% for pa-
tients >70 years. Schwarz et al. evaluated QLQ-C30 data
for the general german population [25] and described
global health scores of 65.6% and 61.5% for patients ≤70
and >70 years, respectively. When compared to the gen-
eral german population, patients after HIFU treatment
show better quality of life with respect to global health
scores. Drummond et al. evaluated quality of life after
standard therapy in more than 6000 patients within the
PiCTure study (prostate cancer treatment, your experi-
ence) [8]. They described global health scores ranging
from 73.4% for radical prostatectomy and 69.4% for ex-
ternal beam radiation therapy. With respect to the
younger patient collective in the PiCTure study, global
health score after HIFU treatment in our collective
ranged within the scores after standard treatment op-
tions described by Drummond et al. Comparing the re-
sults of QLQ-PR25 items revealed more urinary
symptoms (28.3% for HIFU vs. 19.8% for standard treat-
ment [8]) and more urinary bother (38.6% for HIFU vs.
15.6% for standard treatment [8]) and less sexual activity
(56.9% for HIFU vs. 67.8% for standard treatment [8]).
Limitations of the study include short followup. Results
predicting oncological safety need longer followup pe-
riods, that should be considered in further studies. An-
other limitation is the missing, preoperative assessment
for quality of life to compare changes for this parameter.
Conclusion
In conclusion, HIFU treatment for localized prostate
cancer shows acceptable oncological safety in limited
follow up. However, local recurrence is not always indi-
cated by biochemical recurrence. Compared to literature,
the quality of life after HIFU showed better results com-
pared to general population of equivalent age. Patients’
satisfaction ranges within those of standard treatment
options. Further studies are needed to compare changes
in quality of life before and after HIFU therapy. In
addition, nearly 25% of patients needed further treat-
ment for bladder neck obstruction. HIFU seems a safe
valuable treatment alternative for patients not suitable
for standard treatment.
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